Medical network on July 26 - July 14, shenzhen genomics co., LTD in shenzhen stock exchange listed on the gem trade, raise money amount is 547 million yuan, offering price of 13.64 yuan/share, become the shenzhen stock exchange 2001 listed companies. As the largest provider of high-throughput gene sequencing services and equipment in China, the growth and pull effect of leading enterprises in the field of gene sequencing is obvious.
New technologies and new requirements have transformed the role of gene sequencing, precision medicine, and related equipment and equipment from technology ports to health management platforms. Medical surrounding life big data, industry chain on the middle and lower reaches of the return to nature of health management, clinical diagnosis and treatment, data and business logic depth, hasten traditional gene sequencing and related equipment into the pharmaceutical industry chain.
Data integration into clinical needs
In recent years, the global genomics technology industry has achieved breakthrough, industry a good momentum of development, scientific research, medical and health institutions and ordinary people acceptance of gene sequencing is higher and higher. According to BCCResearch, the gene sequencing industry is expected to maintain rapid growth, with a market size of $13.8 billion in 2020 and an annual compound growth rate of 18.7 percent.
Because of genetic technology must be based on a large number of large-scale application based on the accumulation of genetic data and interpretation, so product of gene sequencing and bioinformatics analysis is the bottleneck of genetic testing market segment and the core, the data interpretation and services is the industry's most valuable part, reflects the genes of the company's research and development strength, advanced technology and capability of enterprises with the life and health industry's core competitiveness.
In the recently held in shenzhen, "the second genome cloud computing technology developers conference", United Electronics Co., Ltd., chairman wang donghui, according to the big data generated based on genetic testing and precision medical industry, the future development direction mainly includes data service for the end user B and C for end users to provide health management. "Subverts the traditional information analysis centered on computing technology architecture, into a 'data to life as the center; in the aspect of medical digital, surrounding the medical intelligent auxiliary diagnosis, image three dimensional visualization system, treatment the disease from dependence on two-dimensional experience into a three-dimensional, quantifiable digital system, significantly improve the diagnostic precision."
From academic breakthrough to tool localization, Chinese gene sequencing device products and testing clinical services are gradually integrated into the core industrial chain of medicine. Wuxi group enterprise clear biological, chief technology officer, China director, says Dr Sun Hongye genetic data only exchange can create value, and analysis is the basis of the calculation and sharing of the standard, only rely on standardized computing and analysis of product large queue to support clinical research and drug development, in three stages: from the input, process, results provide process and visualization analysis.
Patients by an American CLIA certification laboratory as an example, the level of its clinical samples for sequencing data, reference for patients' sequencing data, using genome annotation and clinical sequence analysis tools, search through data splicing and mutation, to depth ratio on whole genome data analysis of low frequency variation, sequencing and interpretation have irreplaceable importance and uniqueness. Obviously, from infectious diseases to genetic birth defects and malignant tumor, from accurate diagnosis, treatment to rehabilitation, gene sequencing and related equipment products will provide accurate detection more fully, perfect solutions and competitive price, meet is not meet the clinical needs.
Horizontal resource coordination and cooperation
Innovative manufacturing is characterized by intellectualization and requires Chinese pharmaceutical companies to improve operational efficiency with new technologies. Precision medical treatment is the future trend of the development of medical industry, the accurate health development must be based on a large data platform, because platform operation and data service is an important part of the biological medical industry development, infrastructure suppliers together with the method of joint operations, to medical institutions and sequencing data providers such as enterprise provide industry support.
Notable is, from the perspective of life big business enterprise of data providers, including genomics, grain to the source, the golden field of da an gene, inspection, wuxi, etc., data needs to be a "memory, pipe, calculate," powerful core function support, in order to realize the data distributed storage space application, solve the storage space and decoupling, hierarchical deployment, data persistence, data scheduling data discovery, dynamic reconfiguration, information analysis, such as across the cluster distributed computing complexity problem.
As the human genome sequencing costs down, "Moore's law" speed to match the cost of genomic data analysis is declining, especially in 2016 up to now, just a year, gene as a decline in the cost of data analysis much faster than the speed of gene sequencing costs down. Now, the cost of a single person's total genome data analysis has been reduced to within 100 yuan.
Big data analysis including ten steps, if every enterprise to do data analysis in the face of different steps to choose differentiation method, how to organize different tools better and efficiently allocate computing tasks, this is the whole genome sequencing, cloud computing, instrument equipment research and development, such as hardware and software companies are working to optimize strategic work. Li sharrong, CEO of GeneDock, a beijing-based company, pointed out that not only do each enterprise focus on its own underlying data optimization, it also needs cross-step coordination of the industrial chain. "Including the GATK algorithm optimization, accelerate the calculation operation process, reduce the CPU overhead, and, along with industrial partners, will be the encapsulation technology, data compression, storage solution; gene sequencing company also needs to adjust the data into a distributed, and collaborative development procedures, more easy to use."
Genomics, said CEO Yin Ye testing costs down, now is not a single company with mining technology can solve, "from the upstream equipment manufacturers of medical equipment, to the middle reaches of gene sequencing, downstream to the health service platform, genetic testing industry based on the life data of each ring must be Shared, for, sharing; the industry by 2020 to a single person's whole genome sequencing and analysis of the total cost control within 2000 yuan RMB, the data analysis process standardization and cost is falling fast, is expected to achieve expected industry ahead of time." |
